ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that the last patient has been enrolled in the confirmatory Phase 3 clinical trial of BromSite™ (ISV-303) for the reduction of inflammation and pain after cataract surgery. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision’s DuraSite® drug delivery technology. Pharm-Olam International served as the contract research organization (CRO) managing the BromSite study on behalf of InSite Vision.
Help employers find you! Check out all the jobs and post your resume.
